Symbols

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

LKFT

Lakefront Biotherapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LKFT

Lakefront Biotherapeutics Nv

Cell therapy SPAC,layout CAR-T,autologous cell drug startups

Industry

Biotechnology Ⅲ

Established Date

06/30/1999

Listing Date

05/14/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

452

Fiscal Year Ends

12-31

Website

www.glpg.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Schalienhoevedreef 20T, 2800 Mechelen, Belgium

Business

Develops and delivers medicines.

Introduction

Lakefront Biotherapeutics NV was incorporated in Belgium on June 30, 1999. The company is a global biotechnology company with operations in Europe and the United States that develops translational medicines for more years of life and quality of life. The company focuses on highly unmet medical needs, synergizing compelling science, technology and collaborative approaches to create a deep pipeline of potentially best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology.

Company Financials

EPS

LKFT has released its 2026 Q1 earnings. EPS was reported at 0.25, versus the expected -0.95, beating expectations. The chart below visualizes how LKFT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LKFT has released its 2026 Q1 earnings report, with revenue of 7.46M, reflecting a YoY change of -90.78%, and net profit of 16.69M, showing a YoY change of 110.08%. The Sankey diagram below clearly presents LKFT's revenue sources and cost distribution.